su011248
Kidney Neoplasms
PfizerPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Kidney Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Axitinib Pfizer | Phase 3 | BB |
Ipilimumab Pfizer | Phase 4 | BB |
Nivolumab Bristol-Myers Squibb | Phase 4 | BB |
DROPERIDOL RenJi Hospital | Phase 4 | BB |
FENTANYL RenJi Hospital | Phase 4 | BB |
View all 47 →
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →